Direkt zum Inhalt
Merck

Striatal dopamine receptor plasticity in neurotensin deficient mice.

Behavioural brain research (2014-12-03)
Lucy G Chastain, Hongyan Qu, Chase H Bourke, P Michael Iuvone, Paul R Dobner, Charles B Nemeroff, Becky Kinkead
ZUSAMMENFASSUNG

Schizophrenia is thought to be caused, at least in part, by dysfunction in striatal dopamine neurotransmission. Both clinical studies and animal research have implicated the dopamine neuromodulator neurotensin (NT) in the pathophysiology of schizophrenia. Utilizing male mice lacking the NT gene (NT(-/-)), these studies examined the consequences of NT deficiency on dopaminergic tone and function, investigating (1) dopamine concentrations and dopamine receptor and transporter expression and binding in dopaminergic terminal regions, and (2) the behavioral effects of selective dopamine receptor agonists on locomotion and sensorimotor gating in adult NT(-/-) mice compared to wildtype (NT(+/+)) mice. NT(-/-) mice did not differ from NT(+/+) mice in concentrations of dopamine or its metabolite DOPAC in any brain region examined. However, NT(-/-) mice showed significantly increased D1 receptor, D2 receptor, and dopamine transporter (DAT) mRNA in the caudate putamen compared to NT(+/+) controls. NT(-/-) mice also showed elevated D2 receptor binding densities in both the caudate putamen and nucleus accumbens shell compared to NT(+/+) mice. In addition, some of the behavioral effects of the D1-type receptor agonist SKF-82958 and the D2-type receptor agonist quinpirole on locomotion, startle amplitude, and prepulse inhibition were dose-dependently altered in NT(-/-) mice, showing altered D1-type and D2-type receptor sensitivity to stimulation by agonists in the absence of NT. The results indicate that NT deficiency alters striatal dopamine receptor expression, binding, and function. This suggests a critical role for the NT system in the maintenance of striatal DA system homeostasis and implicates NT deficiency in the etiology of dopamine-associated disorders such as schizophrenia.

MATERIALIEN
Produktnummer
Marke
Produktbeschreibung

Sigma-Aldrich
Acetonitril, suitable for HPLC, gradient grade, ≥99.9%
Sigma-Aldrich
Acetonitril, HPLC Plus, ≥99.9%
Sigma-Aldrich
Natriumhydroxid, ACS reagent, ≥97.0%, pellets
Sigma-Aldrich
Natriumhydroxid, reagent grade, ≥98%, pellets (anhydrous)
Sigma-Aldrich
Phosphorsäure, ACS reagent, ≥85 wt. % in H2O
Sigma-Aldrich
Natronlauge, 50% in H2O
Sigma-Aldrich
Acetonitril, ACS reagent, ≥99.5%
Sigma-Aldrich
Acetonitril, anhydrous, 99.8%
Sigma-Aldrich
Phosphorsäure, 85 wt. % in H2O, 99.99% trace metals basis
Sigma-Aldrich
Acetonitril, for HPLC, for UV, ≥99.9% (GC)
Sigma-Aldrich
Natronlauge, BioUltra, for molecular biology, 10 M in H2O
Sigma-Aldrich
Phosphorsäure, ACS reagent, ≥85 wt. % in H2O
Sigma-Aldrich
Acetonitril, suitable for HPLC, gradient grade, ≥99.9%
Sigma-Aldrich
Natronlauge, 1.0 N, BioReagent, suitable for cell culture
Sigma-Aldrich
Phosphorsäure, puriss. p.a., ACS reagent, reag. ISO, reag. Ph. Eur., ≥85%
Sigma-Aldrich
Natriumhydroxid, BioXtra, ≥98% (acidimetric), pellets (anhydrous)
Sigma-Aldrich
Bromwasserstoffsäure, ACS reagent, 48%
Sigma-Aldrich
Natriumhydroxid, puriss. p.a., ACS reagent, reag. Ph. Eur., K ≤0.02%, ≥98%, pellets
Sigma-Aldrich
Natriumhydroxid, reagent grade, 97%, powder
Sigma-Aldrich
Natriumhydroxid, puriss., meets analytical specification of Ph. Eur., BP, NF, E524, 98-100.5%, pellets